Status:
COMPLETED
Dexlansoprazole MR-Based Concomitant Quadruple Therapy
Lead Sponsor:
Chang Gung Memorial Hospital
Conditions:
Helicobacter Pylori Infection
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Background: Recommended proton pump inhibitor (PPI)-clarithromycin-amoxicillin or metronidazole treatment for 7 to14 days is the first choice treatment for H pylori infection. The eradication rate of...
Detailed Description
Background: Recommended proton pump inhibitor (PPI)-clarithromycin-amoxicillin or metronidazole treatment for 7 to14 days is the first choice treatment for H pylori infection. The eradication rate of...
Eligibility Criteria
Inclusion
- H. pylori-infected outpatients with endoscopically proven peptic ulcer diseases or gastritis.
Exclusion
- Previous H. pylori-eradication therapy
- ingestion of antibiotics, bismuth, or PPIs within the prior 4 weeks
- patients with allergic history to the medications used
- patients with previous gastric surgery
- the coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia)
- pregnant women.
Key Trial Info
Start Date :
March 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 20 2019
Estimated Enrollment :
202 Patients enrolled
Trial Details
Trial ID
NCT03829150
Start Date
March 1 2017
End Date
April 20 2019
Last Update
May 14 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaohsiung Chang Gung Memorial Hospital,Taiwan
Kaohsiung City, Taiwan, 833